Medical Licensing (MD/DO) · Independent exam preparation
ESEGH: Specialist Gastroenterology and Hepatology Decision Guide Study Guide
Practise specialist decisions in gastroenterology and hepatology: interpret investigations, distinguish induction from maintenance treatment, recognise diagnostic traps and select evidence-based management.
By CertMedbry · Updated 19 October 2026
Practise choosing the next investigation, interpreting discordant results and selecting appropriate management across all ten ESEGH blueprint domains. Particular emphasis falls on colonic disease and hepatology, which together account for approximately 40% of the indicative blueprint. Teaching includes IBD treatment, biliary emergencies, cirrhotic ascites, pancreatic disease, nutritional complications, small-bowel disease, salivary dysfunction and anal presentations. The 60 concepts are selective: the official examination blueprint defines the full examination scope. Its domain counts do not prescribe quotas for individual subtopics.
Try 20 free practice questionsWhat is the exam format?
Check the question types, timing and outline before planning your revision.
Which examination and professional level does this guide address?
This guide addresses the European Specialty Examination in Gastroenterology and Hepatology, a pan-European specialist knowledge assessment delivered through the ESBGH, Federation and BSG partnership. It assesses knowledge expected of a specialist in gastroenterology and hepatology. Requirements for training completion or specialist recognition depend on the relevant jurisdiction.
European Specialty Examination in Gastroenterology and Hepatology — ESBGH · European Specialty Examination in Gastroenterology & Hepatology — The Federation
How do EBGH, the Gastroenterology SCE and ESEGH relate?
The Federation documents that ESEGH replaced the Gastroenterology SCE and the European Section and Board examination in January 2018. EBGH is therefore a historical predecessor label in this context. The Federation states that successful candidates may use ESE (Gastroenterology).
European Specialty Examination in Gastroenterology & Hepatology — The Federation · European Specialty Examination in Gastroenterology and Hepatology — ESBGH
How many questions are there, and how long does the examination last?
The official format is 200 questions across two three-hour papers, with 100 questions in each paper. Questions use a best-of-five format: one preferred answer and four plausible alternatives.
European Specialty Examination in Gastroenterology & Hepatology — The Federation · European Specialty Examination in Gastroenterology and Hepatology — ESBGH
What delivery arrangements are announced for the next sitting?
The ESBGH announcement lists the next examination as 7 April 2027, with registration opening on 16 December 2026. Its specific 2027 notice states that candidates will attend test centres in Europe and elsewhere, and that home sitting will no longer be possible. Consult the examination providers for subsequent updates and application arrangements.
European Specialty Examination in Gastroenterology and Hepatology — ESBGH
Which blueprint applies, and how are its domains weighted?
The current Federation-linked blueprint has indicative counts of: Biliary tree 16; GI haemorrhage 10; Inflammatory bowel disease and colonic disorders 40; Liver disorders 40; Nutrition 10; Oesophageal disorders 16; Pancreatic disorders 16; Small intestinal disorders 20; Stomach and duodenal disorders 20; Other 12. These total 200, corresponding to 8%, 5%, 20%, 20%, 5%, 8%, 8%, 10%, 10% and 6%. Counts may vary slightly and span both papers. The document prints no version or effective date. These are domain allocations, not individual subtopic quotas.
ESEGH Examination Blueprint · European Specialty Examination in Gastroenterology & Hepatology — The Federation
How does the Blue Book relate to this selective guide?
The ESBGH curriculum page lists the UEMS-approved Blue Book 2023. Examination-page prose also retains a reference to the older 2017 edition. This guide does not reproduce every curriculum competency. Other includes mouth and salivary gland disorders, endoscopy, physiology, investigations, symptoms and signs, and anal disorders. The official examination outline remains the full scope for study.
The Blue Book — ESBGH · European Specialty Examination in Gastroenterology and Hepatology — ESBGH · ESEGH Examination Blueprint
How should the practice questions and flashcards be used?
The 20 questions are independent, original, four-option single-best-answer drills. They differ from the official five-option format and do not simulate an entire examination or predict passing. Their allocation, and that of the 20 flashcards, broadly follows the indicative domain weights, with rounding to preserve every domain. Review the reasoning for each alternative, then revisit the corresponding concept and primary guidance. Answer indices run from zero to three.
ESEGH Examination Blueprint · European Specialty Examination in Gastroenterology and Hepatology — ESBGH
This independent guide develops clinical reasoning through mechanisms, discriminating findings, applications and common errors. Interpret each investigation in relation to disease probability, sampling adequacy and the management decision it must inform. Distinguish treatment that induces remission from treatment that maintains it, and recognise findings that require escalation.
Outline used: Current Federation-linked ESEGH Examination Blueprint, verified 2026-10-10; the one-page document states no version or effective date. The workbook's EBGH label maps to the predecessor examination replaced by ESEGH in January 2018, as explicitly documented by the Federation. The assigned slug is preserved. The ESBGH curriculum landing page lists the UEMS-approved Blue Book 2023; its full document could not be retrieved, so detailed curriculum coverage is based on the opened examination blueprint.
60 key concepts: understand, apply and avoid the traps
Work through the questions by exam domain. Explain the answer in your own words, try the example, then check the common pitfall.
Biliary tree8%
1.Which initial tests establish the likelihood of common bile duct stones?
Liver biochemical tests and transabdominal ultrasound are the initial investigations for suspected common bile duct stones. Ultrasound can demonstrate duct dilatation or a duct stone, while biochemical cholestasis supports obstruction. Neither a normal duct diameter nor a negative ultrasound reliably excludes a small stone. The decision to investigate further depends on the combined clinical, biochemical and imaging picture, rather than any isolated result or a transient improvement in pain.
Apply it
A patient has episodic right upper quadrant pain, raised bilirubin and gallbladder stones, but no duct stone on ultrasound. Persistent biochemical suspicion warrants further duct imaging rather than reassurance from the ultrasound alone.
Common pitfall: Gallbladder stones establish cholelithiasis, but do not prove duct stones; conversely, an ultrasound without a visible duct stone does not exclude choledocholithiasis.
Endoscopic management of common bile duct stones — ESGE Guideline
2.When should EUS or MRCP precede ERCP?
When suspicion of duct stones persists but initial tests do not establish the diagnosis, endoscopic ultrasound or magnetic resonance cholangiopancreatography can confirm stones without exposing everyone to therapeutic ERCP risks. ERCP is primarily a treatment procedure because pancreatitis, bleeding and perforation are meaningful complications. EUS can be particularly useful for small stones, whereas MRCP provides noninvasive duct imaging. Availability, contraindications and the probability of needing immediate therapy influence the choice.
Apply it
A stable patient has fluctuating cholestatic tests and a mildly enlarged common bile duct, with no definite stone. Arrange EUS or MRCP to clarify the diagnosis before committing the patient to therapeutic ERCP.
Common pitfall: Proceeding directly to diagnostic ERCP treats uncertainty as proof of obstruction and exposes patients without stones to an avoidable procedure and complications.
Endoscopic management of common bile duct stones — ESGE Guideline
3.How does cholangitis severity determine biliary drainage urgency?
Acute cholangitis combines biliary infection with impaired drainage, so antibiotics and resuscitation may not provide definitive source control. Severity determines drainage urgency. ESGE recommends drainage as soon as possible in severe disease, and within 12 hours when septic shock is present. Moderate cholangitis generally requires drainage within 48–72 hours. Clinical deterioration, organ dysfunction and shock carry greater urgency than the bilirubin value or the apparent size of the obstructing stone.
Apply it
A patient with a duct stone becomes hypotensive despite initial fluids and requires vasopressors. Start antimicrobial treatment and arrange urgent endoscopic drainage alongside resuscitation, rather than waiting for several days of antibiotic response.
Common pitfall: Falling temperature after antibiotics does not establish adequate source control when obstruction and organ dysfunction persist; shock makes delayed elective clearance inappropriate.
Endoscopic management of common bile duct stones — ESGE Guideline
4.Why is temporary biliary stenting useful after unsuccessful stone extraction?
A temporary plastic biliary stent can restore drainage when a duct stone cannot be removed safely during the initial ERCP. This separates immediate decompression from definitive stone clearance and may facilitate subsequent treatment. The stent is a bridge, with a documented plan for repeat ERCP, clearance and stent removal or exchange. Retained stents can obstruct and cause recurrent cholangitis, so successful initial drainage does not eliminate the need for follow-up.
Apply it
An elderly patient has cholangitis and an impacted stone that resists initial extraction. After effective drainage with a plastic stent, arrange a scheduled definitive procedure and communicate the stent follow-up plan before discharge.
Common pitfall: Treating a temporary stent as permanent definitive stone management invites occlusion and recurrent infection, particularly when follow-up responsibility is unclear or undocumented.
Endoscopic management of common bile duct stones — ESGE Guideline
5.Which endoscopic approaches help clear difficult duct stones?
Difficult stones may require techniques beyond standard balloon or basket extraction. Limited sphincterotomy combined with endoscopic papillary large-balloon dilation is an established first-line approach for difficult common bile duct stones. Cholangioscopy-assisted electrohydraulic or laser lithotripsy can fragment resistant stones. Treatment must account for the distal duct diameter, strictures and local expertise. Enlarging the papillary opening cannot safely compensate for an unrecognised downstream narrowing or an excessively large stone.
Apply it
A large duct stone remains after standard extraction attempts, and the distal duct has no stricture. An experienced endoscopist considers limited sphincterotomy with appropriately sized large-balloon dilation, reserving lithotripsy if extraction remains unsuccessful.
Common pitfall: Forceful extraction or balloon dilation beyond the safe distal duct diameter increases harm; difficult anatomy should change the technique rather than the force.
Endoscopic management of common bile duct stones — ESGE Guideline
GI haemorrhage5%
6.Why does adrenaline injection need a second haemostatic modality?
In an actively bleeding peptic ulcer, injected adrenaline can slow bleeding through local tamponade and vasoconstriction, improving visibility. Its effect is insufficiently durable as sole definitive treatment. Endoscopic management therefore combines adrenaline, when used, with a mechanical or thermal modality that secures haemostasis. The decisive distinction is between temporary control that permits treatment and durable treatment of the bleeding vessel. Device selection depends on ulcer anatomy, vessel characteristics and available expertise.
Apply it
An oozing duodenal ulcer becomes easier to inspect after adrenaline injection. The endoscopist then applies definitive mechanical or thermal haemostasis instead of ending the procedure because visible bleeding has temporarily stopped during inspection.
Common pitfall: Immediate cessation after adrenaline is a tempting endpoint, but it can conceal a continuing risk of recurrent bleeding from an inadequately treated vessel.
Endoscopic diagnosis and management of peptic ulcer bleeding — ESGE Guideline, Update 2026
7.Which ulcer stigmata do not require endoscopic haemostasis?
A clean ulcer base and a flat pigmented spot are low-risk endoscopic stigmata and do not require endoscopic haemostatic treatment. Active bleeding and a nonbleeding visible vessel represent a different risk category. Management still includes appropriate acid suppression, assessment of the bleeding cause and attention to antithrombotic or ulcerogenic medication. The endoscopic appearance guides whether a vessel requires treatment; the mere presence of a recent bleeding history does not make every ulcer suitable for clipping.
Apply it
After stabilisation for melaena, a patient has a duodenal ulcer with a clean base and no visible vessel. Provide medical ulcer treatment and assess overall discharge suitability, without applying prophylactic clips to normal-looking ulcer tissue.
Common pitfall: Confusing a flat pigmented spot with a protruding visible vessel leads to unnecessary intervention; classify the actual stigma before choosing endoscopic haemostasis.
Endoscopic diagnosis and management of peptic ulcer bleeding — ESGE Guideline, Update 2026
8.How should recurrent bleeding after successful ulcer haemostasis be managed?
Clinical evidence of recurrent ulcer bleeding prompts renewed resuscitation and repeat therapeutic endoscopy. Rebleeding does not automatically mean that endoscopic treatment has been exhausted. A further endoscopic attempt, including an appropriate cap-mounted clip where indicated, can achieve control. If repeat endoscopic haemostasis fails, transcatheter arterial embolisation is generally the next escalation where available. Surgery remains relevant when embolisation is unavailable or unsuccessful. The sequence depends on current instability, technical feasibility and local access.
Apply it
A patient develops fresh haematemesis and circulatory compromise the day after ulcer clipping. Resuscitate and arrange repeat therapeutic endoscopy; if endoscopic control fails again, escalate promptly to arterial embolisation with surgical involvement as needed.
Common pitfall: Routine repeat endoscopy in every stable patient differs from repeat treatment for clinical rebleeding; neither immediate surgery nor watchful waiting fits every recurrence.
Endoscopic diagnosis and management of peptic ulcer bleeding — ESGE Guideline, Update 2026
Inflammatory bowel disease and colonic disorders20%
9.How should biopsies be distributed when inflammatory bowel disease is first suspected?
Initial assessment of suspected inflammatory bowel disease requires ileocolonoscopy with biopsies from multiple defined segments, including affected and apparently unaffected mucosa. Histology adds information about chronicity, distribution and alternative causes that the endoscopic appearance alone cannot establish. Site-labelled specimens preserve the relationship between inflammation and anatomy. A limited sample from the most inflamed area may confirm inflammation but fail to distinguish disease patterns or identify involvement beyond the visibly abnormal segment.
Apply it
A patient with bloody diarrhoea has left-sided inflammation at colonoscopy. When safe, inspect the terminal ileum and remaining colon, taking separately labelled segmental biopsies rather than sampling only the most dramatic distal lesion encountered.
Common pitfall: A single inflamed biopsy cannot reliably map disease extent or establish a complete IBD phenotype; apparent normality elsewhere does not remove the value of sampling.
Endoscopic tissue sampling — Part 2: Lower gastrointestinal tract. ESGE Guideline
10.How do induction and maintenance treatment differ in mild-to-moderate ulcerative colitis?
Oral mesalazine at least 2 g/day induces remission; adding rectal mesalazine addresses distal inflammation in proctosigmoiditis or more extensive disease. Mesalazine can also maintain remission. Corticosteroids provide induction treatment, but should not maintain remission. Relapse during steroid tapering or repeated steroid courses requires a steroid-sparing strategy. See the [ECCO medical treatment guideline](https://academic.oup.com/ecco-jcc/article/20/7/jjag066/8726617) and [maintenance evidence](https://academic.oup.com/ecco-jcc/article/16/1/2/6390052).
Apply it
Persistent distal symptoms on oral mesalazine warrant checking adherence and adding appropriate rectal treatment. After steroid-induced improvement, establish maintenance therapy.
Common pitfall: Symptom suppression with continued prednisolone does not constitute successful maintenance; dependence signals inadequate disease control.
11.Why are biopsies necessary when microscopic colitis is suspected?
Microscopic colitis commonly causes chronic watery, nonbloody diarrhoea despite a normal or near-normal colonoscopic appearance. Diagnosis depends on histology, so normal-looking mucosa must still be sampled. ESGE recommends biopsies from both the right and left colon because disease can be unevenly distributed. Separating sites also assists interpretation of normal regional variation. A normal visual examination addresses gross structural disease but does not exclude a microscopic inflammatory explanation for persistent symptoms.
Apply it
An older adult reports months of watery diarrhoea, including nocturnal stools. Colonoscopy looks normal. Obtain right- and left-colon biopsies to evaluate microscopic colitis instead of concluding that normal mucosal appearance establishes a functional disorder.
Common pitfall: Rectal biopsies alone or no biopsies after a normal inspection can miss microscopic colitis; the symptom pattern should determine whether histological sampling is needed.
Endoscopic tissue sampling — Part 2: Lower gastrointestinal tract. ESGE Guideline
12.When should colonic tissue be assessed for cytomegalovirus?
Severe or treatment-refractory colitis, particularly during immunosuppression, should raise concern for cytomegalovirus as a clinically relevant contributor. Targeted biopsies from ulcerated areas, including ulcer bases and edges, improve diagnostic yield. Histology with appropriate ancillary testing helps establish tissue involvement. A blood result alone does not describe the mucosal burden or reliably settle whether CMV is contributing to colitis. Sampling strategy matters because infection may be focal within inflamed tissue.
Apply it
A patient with severe ulcerative colitis remains unwell despite corticosteroids and has deep colonic ulcers. During an appropriately limited safe examination, obtain targeted ulcer biopsies for CMV assessment before assuming that all ongoing inflammation reflects steroid-resistant IBD.
Common pitfall: Escalating immunosuppression without considering tissue infection can miss an important contributor; samples from uninvolved mucosa may also provide falsely reassuring results in ulcerated disease.
Endoscopic tissue sampling — Part 2: Lower gastrointestinal tract. ESGE Guideline
13.Which Crohn's disease treatments illustrate the distinction between induction and maintenance?
Ileal-release budesonide can induce remission in mild-to-moderate Crohn's disease limited to the ileum and/or ascending colon. Corticosteroids should not maintain remission. Thiopurine monotherapy is unsuitable for induction, although it can maintain remission in selected patients after weighing efficacy and adverse effects. Oral mesalazine is not recommended for Crohn's maintenance. Disease location, activity, previous response and steroid dependence determine the need for a steroid-sparing treatment. See the [ECCO Crohn's disease guideline](https://academic.oup.com/ecco-jcc/article/18/10/1531/7693895).
Apply it
A patient repeatedly relapses when budesonide is withdrawn. Reassess activity and select steroid-sparing maintenance rather than indefinitely repeating induction.
Common pitfall: Budesonide's reduced systemic exposure does not make it a maintenance treatment, and thiopurines cannot provide reliable rapid induction.
14.When should acute severe ulcerative colitis escalate beyond intravenous corticosteroids?
Intravenous corticosteroids are first-line inpatient induction treatment. Assess response by day 3: more than eight stools/day, or three to eight with CRP above 45 mg/L, identifies high risk of steroid failure. Initiate rescue and surgical planning; infliximab or ciclosporin are established rescue options. Perforation, uncontrolled haemorrhage or deterioration requires urgent surgical assessment. See the [ECCO treatment guideline](https://academic.oup.com/ecco-jcc/article/20/7/jjag066/8726617) and [Oxford criteria discussion](https://academic.oup.com/ecco-jcc/article/11/7/769/2962457).
Apply it
Ten bloody stools daily despite three days of intravenous steroids requires escalation planning with gastroenterology and colorectal surgery.
Common pitfall: Prolonged ineffective steroids delay rescue or colectomy; thiopurine monotherapy cannot provide rapid rescue.
15.How does high-quality IBD surveillance direct dysplasia sampling?
IBD dysplasia surveillance depends on careful mucosal inspection with high-definition imaging and an appropriate chromoendoscopic technique, followed by targeted sampling of suspicious areas. Random biopsies retain a role in selected high-risk settings, including previous dysplasia or primary sclerosing cholangitis. Good preparation and controlled inflammation improve lesion recognition and histological interpretation. Inspection quality and the patient's risk profile determine the sampling strategy.
Apply it
A patient with longstanding colitis and primary sclerosing cholangitis attends surveillance in remission. Plan meticulous enhanced inspection with targeted sampling, while incorporating additional nontargeted biopsies appropriate to this higher-risk clinical setting.
Common pitfall: Targeted-only sampling should not be applied indiscriminately to every high-risk patient, and random biopsies cannot compensate for poor preparation or hurried mucosal inspection.
Endoscopic tissue sampling — Part 2: Lower gastrointestinal tract. ESGE Guideline
16.Which features favour en bloc assessment of a suspicious colorectal lesion?
A lesion with suspected superficial invasive carcinoma requires an approach that preserves an intact specimen for assessing invasion depth and resection margins. En bloc endoscopic resection may provide this when technically appropriate and deep invasion is not suspected. Piecemeal removal can prevent reliable pathological staging. Conversely, features suggesting deep submucosal invasion may require surgical assessment rather than routine endoscopic resection. Optical characterisation should therefore precede a technique chosen solely by lesion diameter.
Apply it
A colorectal lesion contains a depressed, irregular focus but no definite deep invasion features. Seek expert assessment for an en bloc strategy rather than immediately dividing the lesion into fragments with routine piecemeal EMR.
Common pitfall: Piecemeal resection may eradicate visible tissue while destroying the staging information needed to decide whether an invasive cancer has been treated adequately or needs surgery.
Colorectal polypectomy and endoscopic mucosal resection — ESGE Guideline, Update 2024
17.Why is cold snare preferred for small colorectal polyps?
For colorectal polyps up to 9 mm, cold snare resection removes the lesion with a small rim of normal tissue while avoiding electrocautery injury. Capturing a margin reduces incomplete resection. Cold biopsy forceps are generally inferior for complete removal, especially as lesion size increases. The technique is designed for small lesions without features requiring a different oncological strategy. Lesion size, morphology and optical suspicion remain relevant even when cold snaring is technically easy.
Apply it
A screening colonoscopy identifies a 7-mm sessile polyp without suspicious surface features. Position a cold snare to include the whole lesion and a narrow normal margin rather than repeatedly biting away tissue with forceps.
Common pitfall: A tiny residual rim can remain after poorly positioned snaring; avoiding cautery does not remove the need to inspect the defect for complete resection.
Colorectal polypectomy and endoscopic mucosal resection — ESGE Guideline, Update 2024
18.Which resection approach fits a 10–19-mm nonpedunculated adenoma?
ESGE recommends hot snare polypectomy for nonpedunculated adenomatous polyps measuring 10–19 mm. This recommendation should not be indiscriminately extended to every lesion in that size range: sessile serrated lesions without suspected dysplasia may follow a cold resection strategy. Optical diagnosis, morphology and invasion risk therefore come before technique selection. A lesion that might contain invasive cancer also requires consideration of specimen integrity rather than a size-only decision about snare use.
Apply it
A 15-mm nonpedunculated lesion has optical features of a conventional adenoma without invasion. Select an appropriate hot snare technique, while recognising that an equally sized nondysplastic sessile serrated lesion may warrant a different resection approach.
Common pitfall: Size alone does not make an adenoma, a serrated lesion and a lesion suspicious for cancer interchangeable; their histological and staging implications differ clinically.
Colorectal polypectomy and endoscopic mucosal resection — ESGE Guideline, Update 2024
19.How should large benign-appearing colorectal adenomas be approached?
Large nonpedunculated adenomatous polyps of at least 20 mm are commonly managed by endoscopic mucosal resection in an appropriately experienced service when there is no suspicion of deep invasion. Careful characterisation determines whether piecemeal EMR is acceptable or an en bloc technique is needed. Repeated partial attempts can create fibrosis and complicate definitive treatment. Referral before an unsuccessful resection attempt can preserve technical options and improve the chance of complete, appropriately staged treatment.
Apply it
A general endoscopist finds a 35-mm laterally spreading lesion without obvious deep invasion. Document its morphology and location, then refer for expert resection rather than removing an accessible portion and leaving the remainder behind.
Common pitfall: A large lesion does not automatically require surgery, but casual partial removal can make later endoscopic treatment substantially harder by producing fibrosis and uncertain margins.
Colorectal polypectomy and endoscopic mucosal resection — ESGE Guideline, Update 2024
20.When does prophylactic closure reduce bleeding after conventional hot colorectal EMR?
After conventional electrocautery, or hot, EMR of a large nonpedunculated right-colon lesion, ESGE recommends prophylactic clip closure of the resection defect when feasible to reduce delayed bleeding. Large lesion size and right-colon location identify the setting in which closure has demonstrated benefit. This recommendation should not be extended indiscriminately to cold EMR: avoiding electrocautery gives cold EMR a substantially lower delayed bleeding risk, and routine defect closure is unnecessary.
Apply it
A 30-mm ascending-colon adenoma has been completely removed by conventional hot EMR without immediate bleeding. Close the defect prophylactically when technically feasible because the prevention target is delayed haemorrhage.
Common pitfall: Absence of immediate bleeding does not eliminate delayed bleeding after hot EMR. Conversely, the same routine closure policy is not required after cold EMR.
Colorectal polypectomy and endoscopic mucosal resection — ESGE Guideline, Update 2024
Liver disorders20%
21.When is diagnostic paracentesis required in cirrhotic ascites?
Diagnostic paracentesis is indicated in new-onset ascites and should be performed without delay in patients with cirrhosis and ascites admitted to hospital. Fever, abdominal symptoms, encephalopathy, hypotension or worsening renal function strengthen concern for infection, but their absence does not safely exclude spontaneous bacterial peritonitis. Ascitic cell count and appropriate culture are central investigations. Routine correction of abnormal coagulation tests before uncomplicated paracentesis is not generally required solely because cirrhosis has altered those results.
Apply it
A patient with cirrhosis is admitted with confusion and worsening creatinine but no abdominal pain or fever. Perform diagnostic paracentesis promptly rather than attributing both changes to chronic liver disease without examining the ascitic fluid.
Common pitfall: Waiting for fever or abdominal tenderness misses clinically subtle infection; an elevated INR alone should not automatically delay an otherwise appropriate diagnostic tap in cirrhosis.
Guidelines on the management of ascites in cirrhosis — BSG/BASL
22.How does the serum–ascites albumin gradient identify portal hypertension?
The serum–ascites albumin gradient is serum albumin minus ascitic albumin, using samples obtained close together. A gradient of at least 11 g/L, equivalent to 1.1 g/dL, supports portal hypertension as the mechanism of ascites. It does not establish cirrhosis specifically. Ascitic total protein adds discrimination: cardiac ascites often has a high gradient with relatively high protein. Interpreting the gradient with clinical context is more useful than classifying fluid as an exudate or transudate.
Apply it
Serum albumin is 31 g/L and ascitic albumin is 12 g/L, producing a gradient of 19 g/L. Ascitic protein is 32 g/L and jugular venous pressure is elevated, supporting a cardiac contribution.
Common pitfall: A high gradient identifies portal pressure physiology, not a unique diagnosis of cirrhosis; low serum albumin alone also does not explain every cause of ascites.
Guidelines on the management of ascites in cirrhosis — BSG/BASL
23.Which ascitic neutrophil count establishes the treatment threshold for SBP?
An ascitic polymorphonuclear neutrophil count of at least 250 cells/mm³ is the standard diagnostic threshold for spontaneous bacterial peritonitis in the appropriate setting. Treatment should not await a positive culture. Culture-negative neutrocytic ascites is treated similarly because microbiological sensitivity is imperfect. Bedside inoculation into blood culture bottles improves yield and helps tailor antibiotics. A surgically treatable intra-abdominal source must still be considered when clinical or fluid findings are atypical.
Apply it
A patient with cirrhosis has 420 ascitic neutrophils/mm³ and no evident alternative intra-abdominal source. Obtain appropriate cultures and start empirical treatment immediately rather than waiting overnight for growth.
Common pitfall: Total white cells are not interchangeable with the neutrophil count. A negative culture does not override the threshold; culture-positive fluid with fewer than 250 neutrophils/mm³ requires a different assessment.
Guidelines on the management of ascites in cirrhosis — BSG/BASL
24.When do iron indices and HFE testing establish haemochromatosis?
Haemochromatosis involves impaired hepcidin regulation, increased iron absorption and progressive tissue iron loading. Assess transferrin saturation with ferritin. In HFE p.C282Y homozygotes, EASL accepts biochemical iron overload as sufficient for diagnosis: transferrin saturation above 45% with ferritin above 200 µg/L in females, or saturation above 50% with ferritin above 300 µg/L in males and postmenopausal women. With other genotypes, elevated indices require demonstration of hepatic iron overload by MRI or biopsy.
Apply it
A patient has raised transferrin saturation and ferritin but is not p.C282Y homozygous. Quantify hepatic iron rather than assuming the biochemical pattern and any HFE variant establish haemochromatosis.
Common pitfall: Ferritin rises with inflammation and liver injury, and p.C282Y homozygosity has incomplete penetrance. Neither an isolated ferritin elevation nor genotype alone establishes clinically expressed iron overload.
25.Why is albumin given after large-volume paracentesis?
Removing a large volume of ascites can worsen effective arterial underfilling and trigger circulatory dysfunction, hyponatraemia and renal impairment. After removal of more than 5 litres, the BSG/BASL guideline recommends albumin at 8 g per litre of ascites removed. The calculation uses the full volume removed, not only the amount exceeding 5 litres. Selected higher-risk patients may also merit albumin with smaller-volume drainage, particularly where acute-on-chronic liver failure or kidney injury risk is present.
Apply it
A patient undergoes therapeutic drainage of 7 litres of ascites. Using 8 g per litre, the planned albumin replacement is 56 g, with subsequent monitoring of circulation, sodium and renal function after the procedure.
Common pitfall: Calculating albumin only for the litres above the threshold under-replaces the recommended amount; serum albumin concentration alone does not determine this post-paracentesis indication.
Guidelines on the management of ascites in cirrhosis — BSG/BASL
26.How is initial treatment and response assessment organised in PBC?
Ursodeoxycholic acid at 13–15 mg/kg/day is established first-line treatment for primary biliary cholangitis and is usually continued lifelong if tolerated. Dose adequacy depends on body weight. Biochemical response after one year contributes to risk stratification, alongside bilirubin, platelet count and assessment of fibrosis or cirrhosis. Symptom improvement alone cannot establish disease control because biochemical activity and progression risk may persist despite reduced itch or fatigue.
Apply it
A patient with PBC weighs 70 kg. The recommended daily UDCA range is 910–1050 mg, adapted to available preparations. Check adherence and dose, then assess biochemical response rather than relying on symptoms.
Common pitfall: An inadequate weight-based dose can resemble treatment failure. Conversely, improved symptoms do not remove the need to assess alkaline phosphatase, bilirubin and disease stage.
BSG/UK-PBC primary biliary cholangitis treatment and management guidelines
27.How should diuretic treatment be selected and monitored in cirrhotic ascites?
For a first episode of moderate ascites, spironolactone starting at 100 mg/day is reasonable. Recurrent severe ascites or a need for faster diuresis favours spironolactone 100 mg plus furosemide 40 mg/day, titrated according to response and tolerance. Monitor weight, renal function, sodium and potassium. Hypovolaemic hyponatraemia requires stopping diuretics and restoring circulating volume.
Apply it
Falling sodium with clinical volume depletion during diuresis calls for withholding diuretics rather than intensifying fluid restriction.
Common pitfall: Persistent abdominal fluid can coexist with intravascular depletion; ascites alone does not justify continuing diuresis despite toxicity.
Guidelines on the management of ascites in cirrhosis — BSG/BASL
28.Which hepatitis B markers distinguish current infection, resolved infection and vaccine immunity?
HBsAg indicates current hepatitis B infection. Total anti-HBc marks previous or ongoing natural exposure and is not produced by vaccination alone. Negative HBsAg with positive anti-HBc and anti-HBs usually indicates resolved natural infection; negative HBsAg and anti-HBc with positive anti-HBs supports vaccine immunity. IgM anti-HBc supports recent acute infection, although it can occur during severe flares or reactivation. Persistent HBsAg for at least six months supports chronic infection. Isolated anti-HBc can reflect waning anti-HBs after infection, occult infection or a false-positive result and requires contextual assessment.
Apply it
A patient is HBsAg positive and total anti-HBc positive, with documentation of HBsAg positivity nine months earlier. This supports chronic infection; use virological and liver assessment to characterise disease rather than calling it acute from symptoms alone.
Common pitfall: Anti-HBc is an exposure marker rather than a protective antibody, and a single positive IgM result should be interpreted cautiously during a known chronic infection flare.
29.When does resolved hepatitis B require prophylaxis rather than monitoring during immunosuppression?
Before immunosuppression, assess HBsAg, anti-HBc and baseline HBV DNA in patients with evidence of previous infection. HBsAg-negative, anti-HBc-positive, DNA-negative patients receiving high-risk treatment such as B-cell depletion require prophylaxis with entecavir or tenofovir. Under EASL 2025, moderate- or low-risk regimens can use HBsAg and/or HBV DNA monitoring every three months when reliable; use prophylaxis when monitoring cannot be assured. Detectable baseline HBV DNA requires antiviral management rather than assuming the DNA-negative monitoring pathway applies. Anti-HBs positivity does not eliminate reactivation risk.
Apply it
A patient with resolved HBV, undetectable DNA and planned rituximab needs antiviral prophylaxis. A DNA-negative patient receiving a lower-risk regimen may instead undergo reliable three-monthly virological monitoring.
Common pitfall: Negative HBsAg or positive anti-HBs cannot substitute for baseline DNA testing and regimen-specific prevention. Monitoring is an active scheduled strategy, not observation until hepatitis develops.
EASL-guidelines-May-2025.pdf · Clinical Testing and Diagnosis for Hepatitis B — CDC
30.When should refractory ascites prompt consideration of TIPS and transplantation?
Refractory ascites persists or rapidly recurs despite tolerated treatment, including cases where diuretic complications prevent effective dosing. Consider TIPS to reduce portal pressure and assess transplant suitability. Selection requires caution with current encephalopathy, active infection, hepatorenal syndrome, MELD at least 18 or bilirubin above 50 µmol/L. Repeated paracentesis with appropriate albumin remains an option.
Apply it
Frequent drainage despite tolerated therapy warrants TIPS and transplant assessment; current encephalopathy materially changes TIPS risk.
Common pitfall: Repeated drainage should not obscure the prognostic significance of refractory ascites or the need to assess definitive options.
Guidelines on the management of ascites in cirrhosis — BSG/BASL
31.How is primary biliary cholangitis recognised from unexplained cholestasis?
Persistent cholestatic liver biochemistry, particularly elevated alkaline phosphatase, should prompt exclusion of mechanical obstruction and assessment for primary biliary cholangitis. A compatible biochemical pattern with antimitochondrial antibodies generally establishes the diagnosis without routine biopsy. PBC-specific antinuclear antibodies can support diagnosis when AMA is absent. Histology becomes more important in seronegative disease or when overlap or another process is suspected. Antibody positivity alone, without compatible liver findings, does not establish active cholestatic disease.
Apply it
A patient has persistent alkaline phosphatase elevation, positive AMA and ultrasound without duct obstruction. The combined pattern supports PBC; routine biopsy is not automatically necessary merely to confirm what the compatible serology and biochemistry already establish.
Common pitfall: An isolated positive AMA should not be equated with established active PBC, and a negative AMA does not exclude disease when other specific findings support it.
BSG/UK-PBC primary biliary cholangitis treatment and management guidelines
32.How should phlebotomy endpoints prevent excessive iron depletion?
In confirmed haemochromatosis, phlebotomy removes iron as new erythrocytes are produced. Aim for an induction ferritin endpoint around 50 µg/L, avoiding deliberate further depletion because iron deficiency is harmful. Maintenance generally targets approximately 50–100 µg/L, with intervals adjusted to reaccumulation. Monitor haemoglobin and treatment tolerance throughout, modifying or pausing treatment when necessary. Successful iron depletion does not replace assessment of fibrosis or surveillance indicated by established advanced liver disease.
Apply it
A patient's ferritin reaches approximately 50 µg/L during induction. Move to an individualised maintenance schedule rather than continuing frequent venesection to drive ferritin progressively lower; review haemoglobin and symptoms before subsequent sessions.
Common pitfall: Interpreting an induction target as an instruction to minimise ferritin indefinitely can cause iron deficiency. Persistent transferrin saturation elevation alone should not drive excessive depletion.
Nutrition5%
33.When should enteral nutrition begin in critical illness?
For critically ill adults unable to eat, enteral nutrition is generally preferred when the gastrointestinal tract can be used, with early initiation within 48 hours after appropriate stabilisation. Uncontrolled shock, suspected bowel ischaemia or other major contraindications change that plan. Nutrition should start progressively rather than by forcing full targets immediately. The key physiological distinction is between a perfused, usable gut and one at risk during ongoing haemodynamic instability, not simply whether a feeding tube can be placed.
Apply it
A ventilated patient cannot eat but has stabilised after resuscitation, with no evidence of bowel ischaemia. Begin progressive enteral feeding within the early treatment window, monitoring tolerance rather than waiting for a full oral diet to become possible.
Common pitfall: Early feeding does not justify full-rate nutrition during uncontrolled shock; mechanical tube access alone does not establish that the bowel is ready for feeding.
ESPEN practical and partially revised guideline: Clinical nutrition in the intensive care unit, 2023
34.How should refeeding hypophosphataemia be recognised and managed in the cited ICU pathway?
After undernutrition, carbohydrate delivery increases insulin, promoting intracellular phosphate, potassium and magnesium shifts while increasing metabolic and thiamine requirements. In the ESPEN ICU pathway, refeeding hypophosphataemia is phosphate below 0.65 mmol/L or a fall greater than 0.16 mmol/L. Measure electrolytes two to three times daily and replace deficits. Restrict energy delivery for 48 hours, then increase gradually. These are operational ICU recommendations rather than a universal definition of every refeeding presentation.
Apply it
Within 36 hours of feeding, an undernourished ICU patient's phosphate falls from 1.02 to 0.58 mmol/L. Replace electrolytes, assess thiamine and fluid balance, restrict energy for 48 hours and monitor electrolytes two to three times daily before gradual advancement.
Common pitfall: Normal baseline serum values do not exclude depleted total-body stores. Replacing phosphate while continuing unrestricted energy delivery can perpetuate the driving metabolic disturbance.
ESPEN practical and partially revised guideline: Clinical nutrition in the intensive care unit, 2023
35.Why should energy delivery increase progressively during early critical illness?
During early critical illness, endogenous energy production continues despite external feeding. Immediately delivering full calculated requirements can therefore produce overfeeding, with metabolic and respiratory consequences. ESPEN favours progressive nutrition, using measured energy expenditure when available and avoiding excessive early intake. The target and the rate of approach are separate decisions. A prescription should account for illness phase, tolerance and non-nutritional calories, rather than treating a calculated daily requirement as a mandatory starting infusion rate.
Apply it
An ICU patient receives enteral nutrition plus lipid-containing sedation. Include the sedation's energy contribution and advance feeding progressively, rather than adding full estimated nutritional calories without considering concurrent energy delivery and the early phase of illness.
Common pitfall: A mathematically correct eventual target can still be an inappropriate first-day dose; uncounted non-nutritional calories can also turn a reasonable prescription into overfeeding.
ESPEN practical and partially revised guideline: Clinical nutrition in the intensive care unit, 2023
Oesophageal disorders8%
36.How does high-resolution manometry establish achalasia?
Achalasia reflects impaired oesophagogastric junction relaxation together with absent normal oesophageal peristalsis. High-resolution manometry establishes the motor pattern and distinguishes subtypes using pressurisation and contraction characteristics. An elevated integrated relaxation pressure supports outflow obstruction, but measurements depend on technique and must be interpreted with the entire study. Endoscopy excludes structural causes, while timed barium imaging adds information about emptying. Symptoms alone cannot reliably distinguish achalasia from a mechanical obstruction or another motor disorder.
Apply it
A patient has dysphagia to liquids and solids, with retained oesophageal contents but no obstructing lesion on endoscopy. Arrange high-resolution manometry to define junction relaxation and peristalsis before selecting a treatment directed at the lower sphincter.
Common pitfall: An isolated pressure abnormality is not a complete achalasia diagnosis; normal peristalsis, technical artefact or structural obstruction can change the interpretation and required investigation.
37.Which clues raise concern for malignant pseudoachalasia?
A malignancy at the oesophagogastric junction can mimic achalasia by obstructing outflow or infiltrating neural and muscular structures. Older age, a short symptom history, substantial weight loss and difficulty passing the endoscope through the junction increase suspicion. A visually unremarkable initial mucosal examination does not exclude submucosal or extrinsic disease. CT or endoscopic ultrasound should be considered when these warning features accompany an achalasia-like presentation, rather than proceeding directly to sphincter-disrupting therapy.
Apply it
An older patient develops rapidly progressive dysphagia and marked weight loss over several weeks. Although manometry resembles achalasia, difficult endoscopic passage at the junction warrants further structural investigation before committing to pneumatic dilation or myotomy.
Common pitfall: A manometric achalasia pattern describes physiology, not necessarily its cause; negative superficial biopsies do not reliably exclude an infiltrative junctional malignancy or external compression.
38.Why is timed barium assessment useful after achalasia treatment?
Timed barium oesophagography measures oesophageal emptying at defined intervals and can identify persistent retention after treatment. Symptom improvement and physiological success do not always coincide: patients may adapt eating behaviour despite poor emptying, while persistent symptoms can also arise from reflux or another mechanism. Objective emptying assessment helps distinguish inadequate outflow relief from alternative explanations. It complements, rather than universally replaces, endoscopy and manometry when evaluating recurrent or persistent symptoms after treatment.
Apply it
A patient reports renewed dysphagia after myotomy. Use timed barium imaging to assess retained contrast and integrate endoscopic findings before assuming recurrent sphincter obstruction and arranging another procedure without objective evidence of impaired emptying.
Common pitfall: Symptom scores alone can both underestimate retention and misattribute reflux-related symptoms to recurrent obstruction; repeat intervention should follow a coherent physiological and structural assessment.
39.How should the oesophagus be sampled for suspected eosinophilic oesophagitis?
Eosinophilic oesophagitis can be patchy and may occur despite an apparently normal oesophageal surface. ESGE recommends at least six biopsies from at least two oesophageal levels, targeting abnormal areas where present. Histology is interpreted with symptoms of oesophageal dysfunction and exclusion of relevant alternative explanations. A single distal biopsy has limited sensitivity and may not describe disease distribution. Rings, furrows and exudates support suspicion but do not replace an adequate tissue sampling strategy.
Apply it
A young adult has recurrent food impaction, but the oesophagus looks nearly normal after the bolus is removed. Arrange adequate multilevel biopsies rather than dismissing eosinophilic oesophagitis because classic rings are absent at this examination.
Common pitfall: Normal endoscopic appearance does not exclude eosinophilic oesophagitis, and sampling only one attractive abnormality can miss the patchy distribution of eosinophilic inflammation elsewhere.
40.Which biopsy sites improve diagnosis of viral oesophagitis?
In an immunocompromised patient with odynophagia and oesophageal ulcers, biopsy location should reflect the suspected viral target cells. HSV-associated changes are often found in squamous epithelium at ulcer edges, whereas CMV commonly involves stromal or endothelial cells in the ulcer base. Adequate sampling from both relevant regions can improve diagnostic yield when the cause is uncertain. Endoscopic ulcer shape provides clues, but tissue assessment and appropriate ancillary testing establish the diagnosis more securely.
Apply it
An immunosuppressed patient has painful swallowing and multiple oesophageal ulcers. Sample ulcer edges and bases for directed histological assessment rather than submitting only superficial debris and relying on visual appearance to distinguish HSV from CMV infection.
Common pitfall: The wrong sampling site can produce a false-negative biopsy despite striking ulcers; an endoscopic impression alone does not reliably identify the responsible pathogen in immunosuppression.
Pancreatic disorders8%
41.Why can watery stool produce a falsely low faecal elastase result?
Faecal elastase is reported as a concentration, so excess stool water can dilute the measured value without a true reduction in pancreatic enzyme output. A low result in watery diarrhoea therefore requires caution, especially without pancreatic risk factors or corroborating malabsorption. A repeat sample with appropriate consistency, or laboratory adjustment where available, can clarify the finding. The result should be integrated with nutrition, symptoms and pancreatic history rather than treated as an automatic diagnosis.
Apply it
A patient with profuse watery diarrhoea has a borderline-low faecal elastase but no pancreatic history or weight loss. Repeat or otherwise validate the measurement while investigating diarrhoea, rather than diagnosing permanent pancreatic insufficiency from this sample alone.
Common pitfall: Low concentration is not always low secretion; overlooking dilution can mislabel intestinal diarrhoea as pancreatic disease and delay the correct investigation of persistent symptoms.
Consensus for the management of pancreatic exocrine insufficiency: UK practical guidelines, 2021
42.Which needle is preferred when a solid pancreatic lesion requires EUS-guided tissue acquisition?
ESGE 2025 recommends end-cutting fine-needle biopsy needles over reverse-bevel FNB or fine-needle aspiration needles for solid pancreatic lesions. End-cutting FNB provides histological tissue with preserved architecture, supporting tumour classification, ancillary analyses and distinction from inflammatory conditions. FNA retains a role when rapid on-site cytological evaluation is available. Plan acquisition and specimen processing around the diagnostic question; normal gastric or duodenal mucosal biopsies cannot classify an underlying pancreatic mass.
Apply it
A pancreatic mass requires pathological classification before systemic treatment. Prefer an end-cutting EUS-FNB needle, particularly without rapid on-site cytology, and arrange suitable tissue processing.
Common pitfall: Needle design matters: reverse-bevel FNB is not interchangeable with end-cutting FNB. A nondiagnostic sample does not establish benignity when suspicion remains high.
43.How does infected pancreatic necrosis change intervention timing and technique?
Sterile necrosis does not warrant prophylactic antibiotics. Suspected or proven infected necrosis requires infection-directed management; defer intervention toward four weeks when clinically tolerated so the collection can organise. For infected walled-off necrosis requiring intervention, start with endoscopic or percutaneous drainage according to anatomy and expertise. Failure to improve can require necrosectomy or minimally invasive surgery as a step-up approach. See the [ESGE necrotizing pancreatitis guideline](https://www.esge.com/assets/downloads/pdfs/guidelines/2018_a_0588_5365.pdf).
Apply it
A clinically stable patient with infected necrosis may receive treatment while intervention is deferred; deterioration requires reassessment rather than rigid adherence to a date.
Common pitfall: Necrosis alone does not prove infection. Immediate open necrosectomy is not the default first intervention, and postponement depends on clinical tolerance.
44.What starting enzyme doses make a review of treatment adequacy actionable?
The UK practical guideline recommends adult pancreatic enzyme replacement starting at at least 50,000 lipase units with meals and 25,000 with snacks, adjusted according to response. Distribute the dose through eating so enzymes mix with nutrients; cover nutritional supplements when needed. For persistent symptoms, check adherence, timing, dose, storage and food coverage before escalation or selected use of acid suppression. Persistent diarrhoea despite optimisation warrants assessment for alternatives such as coeliac disease, bile acid diarrhoea or bacterial overgrowth.
Apply it
A patient takes 25,000 lipase units only after each main meal and none with snacks. Correct timing and increase to at least the recommended starting meal and snack doses, then reassess stool symptoms, weight and nutritional status.
Common pitfall: Capsule counts are uninterpretable without capsule strength. Prescribe and review lipase units, and avoid assuming that every continuing symptom requires unlimited dose escalation.
Consensus for the management of pancreatic exocrine insufficiency: UK practical guidelines, 2021
45.When is pancreatic cyst sampling useful, and what do cyst-fluid markers establish?
Sample an indeterminate pancreatic cyst when biochemical analysis and cytopathology could change management. The ESGE 2017 sampling recommendation excepts cysts 10 mm or smaller without high-risk stigmata. Cyst-fluid CEA assists mucinous classification but does not independently diagnose malignancy. ESGE 2025 conditionally favours cyst-fluid glucose over CEA for identifying mucinous cysts. Low glucose supports mucinous classification; neither glucose nor CEA alone establishes high-grade dysplasia or invasive cancer. Integrate cytology, imaging and clinical findings.
Apply it
An indeterminate cyst has competing diagnoses that imply different care. Consider sampling if classification would change management; interpret a low glucose result as evidence about cyst type rather than proof of cancer.
Common pitfall: The 10-mm exception requires absence of high-risk stigmata. A mucinous marker result answers a different question from whether the cyst contains malignancy.
Small intestinal disorders10%
46.Which tests are required when coeliac disease is suspected in selective IgA deficiency?
Initial coeliac serology should pair IgA tissue transglutaminase with total IgA. In selective IgA deficiency with clinical suspicion, the 2026 BSG guideline suggests both IgG-based serology, such as IgG-tTG or IgG-DGP, and duodenal biopsies. Negative IgG testing cannot independently exclude disease in this setting. Document gluten intake because restriction can reduce antibody and histological sensitivity. Symptom improvement on gluten avoidance alone does not establish coeliac disease.
Apply it
A patient eating gluten has iron deficiency, chronic diarrhoea, negative IgA-tTG and selective IgA deficiency. Request IgG-tTG or IgG-DGP and arrange duodenal biopsies rather than using either negative antibody result as sufficient exclusion.
Common pitfall: Switching to an IgG assay corrects an important serological limitation but does not eliminate the need for biopsy in clinically suspected disease with selective IgA deficiency.
The 2026 BSG guidelines on the diagnosis and management of adult coeliac disease
47.How should a suspected small-bowel tumour change the investigation sequence?
When imaging already suggests a small-bowel tumour, ESGE recommends considering device-assisted enteroscopy in preference to capsule endoscopy because enteroscopy can obtain tissue. An uncertain tumour finding on capsule warrants enteroscopic biopsy and localisation, including tattooing when appropriate. A convincing capsule tumour finding also requires cross-sectional staging and assessment of operability. Capsule appearance alone cannot provide histological classification or assess extraintestinal disease.
Apply it
CT identifies a focal jejunal lesion in a patient with anaemia. Consider device-assisted enteroscopy for biopsy rather than using capsule solely to obtain another image of the same suspected tumour.
Common pitfall: An apparent capsule bulge may be misleading, while an actual tumour requires more than mucosal imaging. Match confirmation, localisation and staging to their separate purposes.
Small-bowel capsule endoscopy and device-assisted enteroscopy — ESGE Guideline, Update 2022
48.What minimum duodenal biopsy distribution addresses patchy coeliac disease?
When histological diagnosis is required, the 2026 BSG guideline recommends at least four biopsies from the second duodenal portion and two from the bulb. This distribution addresses patchy and bulb-predominant injury. Proper orientation is essential for assessing villous architecture. Interpret histology with serology, gluten exposure and alternative causes of villous injury. Normal visual appearances do not remove the need for adequate sampling.
Apply it
A patient undergoes endoscopy for suspected coeliac disease. Obtain at least four second-portion and two bulb specimens despite a normal-looking duodenum, preserving site information and ensuring appropriate orientation.
Common pitfall: Six specimens from one location do not reproduce the recommended distribution. Poor orientation can mimic villous shortening, while too few sites can miss genuine patchy injury.
The 2026 BSG guidelines on the diagnosis and management of adult coeliac disease
49.When is HLA testing useful in uncertain coeliac disease?
Coeliac-associated HLA susceptibility is common in people who never develop coeliac disease, so a positive result cannot establish the diagnosis. Its main value is exclusion: absence of compatible susceptibility makes coeliac disease very unlikely. Testing can be useful when serology and histology disagree or when someone has already adopted a gluten-free diet. The test answers whether the genetic background is compatible, not whether gluten is currently causing symptoms or mucosal injury.
Apply it
A patient has uncertain historical coeliac documentation and has avoided gluten for years. HLA testing can help decide whether further coeliac-focused assessment is worthwhile; a compatible result still requires clinical evidence rather than confirming the diagnosis.
Common pitfall: A positive susceptibility genotype is not a disease test because it is common in unaffected people; its stronger diagnostic role lies in a negative compatible-HLA assessment.
The 2026 BSG guidelines on the diagnosis and management of adult coeliac disease
50.How should recurrent iron deficiency and a negative capsule examination be interpreted?
Recurrent or unexplained iron-deficiency anaemia warrants review of prior investigation quality, treatment response and ongoing losses. When small-bowel evaluation is indicated, capsule is a first-line mucosal test in a suitable patient. A high-quality negative examination can support conservative management when the clinical course is reassuring. Continued overt bleeding or a continuing transfusion requirement warrants further investigation with repeat capsule, device-assisted enteroscopy or dedicated small-bowel imaging.
Apply it
After adequate negative conventional endoscopy and capsule examination, a patient's haemoglobin stabilises with iron. Follow the response. If overt bleeding or transfusion dependence continues, investigate further despite the negative capsule.
Common pitfall: A negative capsule is not permanent exclusion of every small-bowel lesion. Its reassurance depends on examination quality and the subsequent clinical course.
Small-bowel capsule endoscopy and device-assisted enteroscopy — ESGE Guideline, Update 2022
51.When should capsule endoscopy follow unexplained overt gastrointestinal bleeding?
When appropriate upper and lower endoscopy have not identified an overt bleeding source and small-bowel bleeding is suspected, capsule endoscopy is a first-line small-bowel investigation in a suitable stable patient. ESGE recommends performing it as soon as possible after the episode, ideally within 48 hours, to improve yield. Device-assisted enteroscopy can then confirm or treat a capsule-detected lesion. Haemodynamic instability or a need for immediate haemostasis may require a different urgent diagnostic and therapeutic pathway.
Apply it
A stable patient has recent melaena with adequate negative gastroscopy and colonoscopy. Arrange early capsule examination while the bleeding episode is recent, then use the location and lesion findings to guide any subsequent therapeutic enteroscopy.
Common pitfall: Delaying capsule for weeks can reduce diagnostic yield, but swallowing a capsule is not a substitute for urgent stabilisation or active haemorrhage control when unstable.
Small-bowel capsule endoscopy and device-assisted enteroscopy — ESGE Guideline, Update 2022
Stomach and duodenal disorders10%
52.How should a negative Helicobacter pylori test during ulcer bleeding be reassessed?
Acute peptic ulcer bleeding, proton pump inhibitors and recent antimicrobial exposure can reduce Helicobacter pylori test sensitivity. A negative index result therefore requires repeat testing after recovery with a planned medication review. When clinically safe, withhold PPIs for at least two weeks before repeat testing to reduce suppression-related false negatives. If infection is identified, eradicate it and document treatment success. Ulcer healing or symptom improvement alone establishes neither absence nor eradication of infection.
Apply it
A rapid urease test is negative during ulcer bleeding after PPI treatment has begun. Arrange reassessment after recovery and, when safe, a PPI-free interval of at least two weeks before the repeat test.
Common pitfall: Repeating testing while the same suppressive conditions persist can reproduce the original false-negative mechanism. Plan recovery and medication timing explicitly.
Endoscopic diagnosis and management of peptic ulcer bleeding — ESGE Guideline, Update 2026
53.How should gastric biopsies improve Helicobacter pylori detection?
Helicobacter pylori distribution can vary across the stomach, particularly with acid suppression or altered mucosa. Sampling both antral and corpus regions improves detection compared with relying on a single site. The reason for testing and recent exposure to proton pump inhibitors, antibiotics or bismuth should inform interpretation of a negative result. Site-aware histology also provides information about the background mucosa. A visually normal stomach does not exclude infection or microscopic gastritis requiring appropriate testing.
Apply it
A patient needs histological assessment for suspected Helicobacter infection and has been receiving acid suppression. Take appropriate antral and corpus samples and document medication exposure so that a negative result is interpreted with its sensitivity limitations.
Common pitfall: A single antral sample may miss redistributed or patchy infection; medication history is part of interpreting histology rather than an unrelated administrative detail on the request.
54.Which biopsy strategy is appropriate for suspected advanced gastric cancer?
An ulcerated or infiltrating gastric lesion suspicious for advanced cancer requires adequate targeted tissue, with ESGE recommending at least six biopsies for suspected advanced gastric malignancy. Samples should target viable abnormal tissue rather than only necrotic debris. A negative superficial result does not overrule a strongly suspicious appearance. This strategy differs from sampling a small superficial lesion intended for endoscopic resection, where excessive biopsies can create fibrosis and complicate subsequent definitive treatment.
Apply it
Endoscopy shows a large irregular gastric ulcer with heaped margins. Obtain multiple targeted biopsies from viable suspicious areas and arrange reassessment if histology is nondiagnostic, rather than accepting a single benign fragment as definitive exclusion.
Common pitfall: Sampling only necrotic slough lowers yield, and benign superficial tissue cannot safely settle a case with persistent endoscopic features strongly suspicious for gastric malignancy.
55.Why does the distribution of gastric atrophy need to be mapped?
The extent and distribution of gastric atrophy or intestinal metaplasia contribute to risk assessment and may suggest different underlying processes. Antral and corpus biopsies should retain their anatomical identity, with additional incisura sampling where appropriate for staging. Combining every sample in one container can obscure whether disease is limited or extensive. Histological mapping complements targeted biopsies of visible lesions; it is not replaced by an isolated positive Helicobacter result or a visually bland examination.
Apply it
A patient has endoscopic features of atrophic gastritis. Obtain site-labelled background biopsies from relevant gastric regions, alongside targeted samples of abnormalities, so pathology can describe distribution rather than merely report that metaplasia exists somewhere in the stomach.
Common pitfall: A positive biopsy establishes a local finding but not its full extent; pooled specimens can lose information needed for meaningful gastric risk assessment and aetiological interpretation.
56.How should suspected linitis plastica be investigated after negative superficial biopsies?
Linitis plastica can infiltrate deeper gastric layers while leaving superficial mucosal samples nondiagnostic. Poor distensibility, thickened folds and an infiltrative appearance should therefore remain concerning despite initially benign biopsies. Repeat targeted and deeper sampling, potentially with endoscopic ultrasound-guided tissue acquisition, can address the mismatch between appearance and histology. The key principle is that a test limited to superficial mucosa cannot reliably exclude a process whose dominant abnormality lies deeper in the gastric wall.
Apply it
A patient has early satiety, weight loss and a rigid poorly distensible stomach, but superficial biopsies show nonspecific inflammation. Pursue deeper tissue assessment and imaging rather than explaining the striking structural findings as uncomplicated gastritis.
Common pitfall: Repeatedly taking identical shallow samples may reproduce the same false reassurance; diagnostic escalation should address the depth of suspected disease rather than merely repeat sampling mechanically.
57.Why should biopsy numbers be limited for an early gastric lesion suitable for resection?
A superficial gastric lesion potentially suitable for endoscopic resection needs histological confirmation without unnecessarily compromising the resection plane. ESGE recommends only one or two targeted biopsies in this setting. Repeated biopsies can induce submucosal fibrosis, making later resection more difficult. This is a different objective from sampling an advanced ulcerated cancer, where obtaining sufficient diagnostic tissue is paramount. Careful optical assessment and early referral help preserve an effective diagnostic and therapeutic pathway.
Apply it
An endoscopist identifies a small superficial gastric lesion without obvious deep invasion and plans expert endoscopic resection. Take limited targeted biopsies and document the lesion carefully rather than repeatedly sampling its entire surface during several examinations.
Common pitfall: Applying an advanced-cancer biopsy protocol to every superficial lesion can create avoidable fibrosis; adequate confirmation does not require maximal tissue removal before planned definitive resection.
Other6%
58.Which tissue approach is useful for a substantial upper gastrointestinal subepithelial lesion?
A subepithelial lesion lies beneath the mucosa, so ordinary superficial forceps biopsies may retrieve normal covering tissue. EUS characterises size, originating layer, echogenicity and other features but cannot distinguish every lesion type. When tissue diagnosis is indicated for a lesion at least 20 mm, the ESGE 2022 subepithelial-lesion guideline recommends EUS-guided fine-needle biopsy or mucosal incision-assisted biopsy equally. Sampling is especially relevant when suspected GIST, high-risk features or planned treatment make classification consequential.
Apply it
A 25-mm gastric subepithelial lesion has nondiagnostic superficial biopsies and requires histological classification. Arrange EUS characterisation and EUS-FNB or mucosal incision-assisted biopsy.
Common pitfall: Normal covering mucosa does not establish a benign underlying lesion. EUS morphology alone may also leave clinically important uncertainty requiring tissue.
59.How can salivary dysfunction contribute to swallowing difficulty and oral disease?
Saliva lubricates food, assists swallowing and protects oral tissues and teeth. Persistent xerostomia can impair chewing and swallowing and increase dental decay and oral fungal infection risk. Review medication causes, head-and-neck radiation and diseases such as Sjögren's disease or diabetes. Examination and salivary-flow assessment can clarify the problem. Management addresses the cause, oral care and symptomatic lubrication or saliva substitution. See [NIDCR guidance on dry mouth](https://www.nidcr.nih.gov/health-info/dry-mouth).
Apply it
A patient struggles with dry foods, reports persistent oral dryness and has new dental decay. Examine the mouth and review medicines and salivary causes as part of the swallowing assessment.
Common pitfall: Persistent dry mouth should not be dismissed as normal ageing. Drinking with food may relieve symptoms without identifying the cause or preventing oral complications.
60.Which anal fissure findings distinguish a typical presentation from one requiring broader investigation?
An anal fissure commonly causes sharp pain during defecation that may persist for hours, with bright red blood on wiping. Most occur in the posterior midline; anterior midline fissures also occur. Lateral or multiple fissures warrant assessment for secondary causes including Crohn's disease, infection and malignancy. Acute fissures usually receive conservative treatment; topical calcium-channel blockers are an option for chronic fissures. See the [ASCRS anal fissure guideline](https://www.ascrsu.com/ascrs/view/ASCRS-Evidence-Based-Guidelines-and-Expert-Consensus/3982013/2/Management_of_Anal_Fissures__2023_).
Apply it
A patient has defecation-related pain and a solitary posterior fissure. Contrast this with multiple lateral lesions, which require evaluation for secondary disease rather than routine treatment alone.
Common pitfall: Bright red bleeding does not establish haemorrhoids. Fissure position, number and associated findings determine whether a typical benign explanation is adequate.
What to focus on during revision
The following are CertMedbry study suggestions. Use the official outline to check the full scope of your examination.
- Give approximately two-fifths of revision time to inflammatory bowel disease, colonic disorders and liver disorders, reflecting their combined indicative blueprint share.
- Practise decision sequences: suspected duct stone to confirmatory imaging or drainage; ulcer bleeding to haemostasis and rebleeding escalation; pancreatic or small-bowel lesions to appropriate classification and staging.
- Distinguish IBD induction from maintenance, recognise steroid dependence and use early response assessment to plan rescue therapy or surgery in severe colitis.
- Interpret measurements with units and context: SAAG, ascitic neutrophils, ferritin, transferrin saturation, faecal elastase and complete hepatitis B serology.
- Learn actionable treatment boundaries: diuretic tolerance and TIPS selection, HBV prophylaxis versus monitoring, pancreatic necrosis intervention timing, meal and snack lipase doses, and ICU refeeding thresholds.
- Make biopsy plans anatomical and question-specific: multilevel oesophageal, four second-portion plus two bulb duodenal specimens, gastric mapping, segmental colonic and targeted ulcer samples.
- Distinguish limited test sensitivity caused by watery stool, IgA deficiency, gluten restriction, acute bleeding, medication exposure or superficial sampling from reliable disease exclusion.
- Extend study beyond these selected concepts using the full official outline, including the wider range of pancreatic, physiological, mouth, salivary and anal disorders. Domain weights do not specify individual subtopic quotas.
A practical preparation plan
1. Map the official scope
Use the ten blueprint domains as your master revision list. Allocate study sessions roughly to the indicative counts, while retaining every domain. Treat these 60 concepts as selected decision exercises rather than a complete curriculum.
2. Build investigation-to-action pathways
For each presentation, write the finding that changes the next action: shock changes drainage urgency, neutrophils change SBP treatment, steroid response changes colitis escalation, and invasion suspicion changes resection strategy.
3. Practise calculations and pattern recognition
Calculate SAAG and post-paracentesis albumin, interpret full HBV marker combinations, and distinguish concentration artefacts from true disease. State units aloud to prevent errors between g/L and g/dL.
4. Answer and explain the alternatives
Complete the 20 drills before reviewing explanations. For every error, identify whether you missed the decisive cue, misread test limitations or chose the wrong treatment sequence. Explain why each alternative is less appropriate.
5. Develop sustained clinical practice
Use progressively longer mixed practice sessions to develop sustained concentration. Review errors after each session, explain the decisive clinical findings and revisit weak domains with current primary guidance and the full specialist curriculum.
Use your sample score as a starting point
The free set contains 20 original practice questions. It is a small learning sample, not an official examination or a validated pass prediction. Review each explanation and its source before moving to another topic.
Start the free sampleOfficial sources and updates
- European Specialty Examination in Gastroenterology & Hepatology — The Federation
- European Specialty Examination in Gastroenterology and Hepatology — ESBGH
- ESEGH Examination Blueprint
- The Blue Book — ESBGH
- Endoscopic tissue sampling — Part 2: Lower gastrointestinal tract. ESGE Guideline
- Small-bowel capsule endoscopy and device-assisted enteroscopy — ESGE Guideline, Update 2022
- Guidelines on the management of ascites in cirrhosis — BSG/BASL
- Guidelines on the Management of Ascites in Cirrhosis — BSG
- BSG/UK-PBC primary biliary cholangitis treatment and management guidelines
- Clinical Testing and Diagnosis for Hepatitis B — CDC
- EASL Clinical Practice Guidelines on haemochromatosis, 2022
- Endoscopic management of common bile duct stones — ESGE Guideline
- European guidelines on achalasia — UEG/ESNM, 2020
- Endoscopic tissue sampling — Part 1: Upper gastrointestinal and hepatopancreatobiliary tracts. ESGE Guideline
- The 2026 BSG guidelines on the diagnosis and management of adult coeliac disease
- ESPEN practical and partially revised guideline: Clinical nutrition in the intensive care unit, 2023
- Endoscopic diagnosis and management of peptic ulcer bleeding — ESGE Guideline, Update 2026
- Consensus for the management of pancreatic exocrine insufficiency: UK practical guidelines, 2021
- Colorectal polypectomy and endoscopic mucosal resection — ESGE Guideline, Update 2024
- 2022_a-1751-5742.pdf
- PIIS01688278220021121.pdf
- guideline_43439.pdf
- 2017_s_0043_109021.pdf
- 2025_a-2524-2596.pdf
- EASL-guidelines-May-2025.pdf
- Dry Mouth | NIDCR
- Management of Anal Fissures (2023) | Evidence-based Guidelines and Expert Consensus
Confirm current eligibility, fees, scheduling and policies directly with the examination provider. CertMedbry is independent and is not endorsed by these organisations. How we handle content and corrections.